Rifampin Capsule Shortage: FDA Update on Availability
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Rifampin Capsules, an anti-infective medication, are experiencing a current shortage for certain dosages, as reported by the FDA, with some presentations available and others discontinued.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 9, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Rifampin.
What's in Shortage
The generic drug Rifampin Capsule, also known by the brand name RIFAMPIN, is currently in shortage. It is available in capsule dosage form and belongs to the therapeutic category of Anti-Infective. The shortage was first posted on 12/22/2021 and last updated on 04/08/2026.
Which Manufacturers Are Affected
The affected manufacturer is Epic Pharma, LLC. Their availability status for various presentations includes:
- Rifampin, Capsule, 150 mg (NDC 42806-801-30): Available
- Rifampin, Capsule, 300 mg (NDC 42806-799-01): Unavailable, with related info on discontinuation of manufacture
- Rifampin, Capsule, 150 mg (NDC 42806-801-01): Unavailable, with related info on discontinuation of manufacture
- Rifampin, Capsule, 300 mg (NDC 42806-799-05): Unavailable, with related info on discontinuation of manufacture
- Rifampin, Capsule, 300 mg (NDC 42806-799-60): Available
- Rifampin, Capsule, 300 mg (NDC 42806-799-30): Unavailable, with related info on discontinuation of manufacture Contact information for Epic Pharma, LLC is (718) 276-8600 ext. 3.
Why There's a Shortage
For the unavailable presentations, the reason provided is the discontinuation of the manufacture of the drug. No specific reason was given for the overall shortage status.
What Patients Should Do
If you rely on Rifampin Capsules, we understand this can be concerning, and we encourage you to speak with your pharmacist or healthcare provider about your prescription needs. You may also contact the manufacturer for more details. Please remember, patients should always consult their healthcare provider for any medication-related concerns and not make changes without professional guidance.
Source
This information is attributed to the FDA Drug Shortages Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,781 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 9, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.